

# Studies in children

Frederica P. Perera and Susan C. Edwards

## Summary

This chapter first discusses the urgent need for prevention of childhood diseases that impose a huge and growing burden on families and society. It provides a review of recent research in this area to illustrate both the strengths and limitations of molecular epidemiology in drawing needed links between environmental exposures and illness in children. For illustration, three of the major diseases in children are discussed: asthma, cancer and developmental disorders. All three impose significant difficulties, have increased in recent decades, and are thought to be caused in substantial part by environmental factors, such as toxic exposures due to lifestyle choices (i.e. smoking and diet),

pollutants in the workplace, ambient air, water and the food supply. These exogenous exposures can interact with “host” factors, such as genetic susceptibility and nutritional deficits, to cause disease. Molecular epidemiology has provided valuable new insights into the magnitude and diversity of exposures beginning *in utero*, the unique susceptibility of the young, and the adverse preclinical and clinical effects resulting from the interactions between these factors. However, molecular epidemiology also faces certain constraints and challenges that are specific to studies of the very young, including ethical issues, technical issues due to the limited amount of biological specimens that can be obtained, and communication of results to

parents and communities. These challenges are particularly apparent when incorporating the newer epigenetic and “omic” techniques and biomarkers into studies of children’s diseases.

## Introduction

Molecular epidemiology, which combines epidemiologic methods and molecular/genetic techniques to measure biomarkers, has been a valuable tool in the study of environmental causes of diseases and disorders in children. Over the past 25 years, the field has made many notable contributions to intervention and prevention efforts that have significantly improved the health of children. These

contributions include the phase-out of lead in gas in the 1970s, which was a result of studies on the negative effects of low-levels of lead on child neurodevelopment, and documentation of the benefits to fetal growth of a 2001 regulation which restricted the use of the pesticide chlorpyrifos (CPF). These positive changes provided the impetus for US federal policies that require agencies to explicitly address risks to children (e.g. the US Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)) and the revised US Environmental Protection Agency's (EPA) Cancer Guidelines (1990s–2000s).

In the context of studies of disease in children, molecular epidemiology has enhanced the power and capabilities of researchers to better delineate mechanisms and causal pathways involved in the exposure-outcome pathway. It has also improved estimates of dose-biologic dosimetry; reduced misclassification of exposure and disease status; augmented the understanding of the variability in individual responses and risk, especially interactions between environment and genes or other susceptibility factors; identified preclinical cases for intervention, thereby enabling earlier interventions; and improved quantitative risk assessment and public policy.

However, molecular epidemiology also faces certain generic constraints and challenges, as well as others that are specific to studies of the very young, including ethical issues, technical issues due to the limited amount of biological specimens that can be obtained, and communication of results to parents and communities. These challenges are apparent in thinking about future directions, such as the incorporation of newer epigenetic and “omics” into studies of children's diseases.

### Context and public health significance: The need for prevention

Between 1980 and 1995, the percentage of children with asthma has doubled in the USA (from 3.6% in 1980 to 7.5% in 1995), and has also increased in other countries (1). An estimated 9 million (12.5%) children aged <18 years in the USA have had asthma diagnosed at some time in their lives (2); an estimated 8.7% (6.3 million) of children had asthma in 2001 alone (1). Rates vary by geographic area and ethnic group; a recent study found that over 25% of elementary schoolchildren in Harlem, New York had asthma (3).

The overall cancer incidence rate increased from the mid-1970s in the USA, but rates in the past decade have been fairly stable (4). Leukaemia is the most common diagnosis for those < 15 years of age, but the relative proportion of it decreases with age: from 36% for those < 5 years of age, to 22% for 10–14-year-olds, and 12% for adolescents 15–19 years of age. Incidence rates in Europe have shown an increase over time since the middle of the last century: the yearly increase averages 1.1% for the 1978–1997 period and ranges from 0.6% for the leukemias to 1.8% for soft-tissue sarcomas (5). According to the databases of population-based cancer registries, which joined forces in cooperative projects such as Automated Childhood Cancer Information System (ACCIS) and EUROCARE, leukemias (34%), brain tumours (23%) and lymphomas (12%) represent the largest diagnostic groups among the < 15 year olds in Europe.

Developmental disabilities, the name given to a broad group of conditions caused by learning or physical impairments, affect an

estimated 17% of children in the USA under age 18 (6). The high rates of these childhood disorders have significant medical-related costs and social impact on individual families and the country as a whole.

Rising rates of asthma and certain cancers, the high rates of developmental disabilities, and the growing evidence that the risk of certain adult diseases is influenced by *in utero* and childhood exposures, indicate that maintaining an “early focus” can have a significant impact on the overall burden of disease (1,7).

### Exposures of concern

Environmental factors, such as toxic exposures due to lifestyle choices (i.e. smoking and diet), pollutants in the workplace, ambient air, water, and the food supply, can interact with ‘host’ factors, such as genetic susceptibility and nutritional deficits, to cause disease. Therefore, there is a need to understand the role of both environmental and susceptibility factors in childhood disease and neurodevelopmental disorders, and to identify the primary environmental toxins affecting them so that preventive measures can be taken.

A focus of this research must be early exposure to toxic chemicals, which has risen exponentially in the past 50 years. Over 80 000 synthetic chemical compounds have been created and registered for commercial use with the US Environmental Protection Agency (EPA) (8), and 2000–3000 new chemicals are submitted for review by the EPA every year (9). Nearly 3000 registered substances are produced in quantities of almost 500 000 kg every year, yet no basic toxicity information is publicly available for 43% of the high volume chemicals manufactured in the USA; a full set of basic toxicity

information is available for only 7% of these chemicals, and there is no information about developmental or paediatric toxicity for 80% (8).

The exposures of concern include genotoxic and non-genotoxic chemicals, as well as chemicals that exert both types of effects. Recent research suggests that endocrine-related cancers, or susceptibility to cancer, may be a result of developmental exposures (10). There is differential exposure of the young to diverse toxic chemicals. During pregnancy and lactation, certain toxicants stored in the bodies of mothers can become bioavailable, exposing the fetus and child. In addition, the fetus and child clear toxicants less readily than an adult (11–15). Young children breathe air closer to the ground, exposing them to particles and vapours present in carpets and soil. While playing and crawling on the floor, children can inhale or dermally absorb toxicants, which are subsequently absorbed more efficiently in children than in adults (16). Compounding the effects of these behaviours is the fact that infants have twice the breathing rate of the average adult. Hand-to-mouth behaviour and thumb sucking habits can also increase exposure.

Dietary habits of children also cause increased exposure to foodborne toxicants. In the USA, children under five years of age eat 3–4 times more food per unit of body weight than the average adult; the average one-year-old drinks 10–20 times more juice than the average adult (17). Dermal exposures may also be higher, as a typical newborn has more than double the surface area of skin per unit of body weight than an adult (18).

### Susceptibility of the young

The biological susceptibility of the young is another important research area. Experimental and human data indicate that the fetus and young child are especially vulnerable to the toxic effects of environmental tobacco smoke (ETS), polycyclic aromatic hydrocarbons (PAHs), particulate matter, nitrosamines, pesticides, polychlorinated biphenyls (PCBs), metals and radiation (11). There is mounting evidence, much of it from molecular epidemiologic studies, that the fetus, infant and child are biologically more sensitive to a variety of environmental toxicants than adults (7,11,19). Specifically, the *in utero* and childhood periods are characterized by rapid physical and mental growth, and gradual maturation of major organ systems. In fact, typical newborns double their weight within six months of birth, while integral parts of the nervous and immune systems are formed during the first six years of life (20). Additionally, sex organ development, myelination, and alveoli formation begin late in pregnancy and continue until adolescence (16). Since cells are proliferating rapidly and organ systems are immature, they are sensitive to the potentially harmful effects of environmental toxins.

Absorption, metabolism and excretion pathways in infants and children differ from those in adults. These pathways dictate the amount of a toxicant, in its various forms, that is present in the body. Epidemiological studies with biomarkers have demonstrated placental transfer of toxicants, and in some cases slower fetal clearance of chemicals such as PAHs, PCBs and mercury (21–23). An infant's kidney filtration rate is lower than an adult's, thus increasing potential susceptibility (16). DNA repair systems are also

immature in the fetus and young child, leading to higher levels of genetic damage per unit of exposure in cord blood leukocytes compared to maternal blood leukocytes (24). Studies have also shown a 65-fold range of variability in sensitivity to the pesticide chlorpyrifos between the most sensitive newborn and the least-sensitive mother (based on paraoxonase 1 (*PON1*) status) (25).

Finally, infants and children have more years of future life than most adults. Thus, there is more time for early exposures to trigger diseases that have long latency periods. For example, early exposure to carcinogens will more likely lead to cancer than the same exposure experienced later in life. In addition, it has been hypothesized that fetal growth restriction due to nutritional deprivation in early life is an important cause of some of the most common, costly and disabling medical disorders of adult life, including coronary heart disease and the related disorders hypertension, stroke and type 2 diabetes (26). It has been proposed that individuals with a 'thrifty phenotype' will have "...a smaller body size, a lowered metabolic rate and a reduced level of behavioural activity... adaptations to an environment that is chronically short of food" (27). This hypothesis, now widely (though not universally) accepted, is known as the Barker Early Origins Hypothesis or thrifty phenotype hypothesis; it is a source of concern for societies undergoing a transition from poor to better nutrition (28). All in all, there is increasing evidence that exposures in early life strongly influence risk of chronic diseases in adulthood, including heart disease and cancer (29).

### **Additional susceptibility factors**

The differential susceptibility of the fetus, infant and child can be influenced by nutritional deficits, genetic predispositions, and psychosocial stressors that can modify (i.e. reduce or increase) the toxic effect of exposures.

### **Nutritional factors**

Micronutrients are known to have major effects on child health and development, and there is evidence that they interact with environmental exposures. Certain micronutrient deficiencies have been associated with childhood asthma, adverse birth outcomes, child development and childhood cancer. For example, essential fatty acid deficiencies are associated with low birth weight, smaller head circumference, and reduced cognitive and motor function (30–32). Antioxidants modulate inflammatory response to air pollution and its effects on childhood asthma (33–35). By removing free radicals and oxidant intermediates, antioxidants protect DNA from the genotoxic, procarcinogenic effects of chemicals that bind to DNA (36,37). Nutritional deficiencies are often closely related to lower socioeconomic status, although variations exist within each socioeconomic bracket.

### **Genetics**

Genetic susceptibility can take the form of common polymorphisms or haplotypes that modulate the individual response to a toxic exposure. For example, two genes have been identified that can increase an individual's vulnerability to organophosphates (OPs), such as chlorpyrifos (CPF), by reducing the reservoir of functioning protective

enzymes (38). The first gene has a prevalence of 4% and results in a poorly functioning form of the enzyme acetylcholinesterase. The second gene results in a relatively inactive form of the enzyme paraoxonase (PON1) (prevalence of 30–38%), an enzyme that detoxifies CPF before the toxin can inhibit acetylcholinesterase (39–41). The effect of CPF on head circumference at birth was significant only among women with low PON1 activity, which could be evidence of an interaction between the *PON1* genotype and OP pesticides (42). However, there are still limited data relating *PON1* to clinical outcomes in individuals exposed to OPs. Other examples of gene–environment interactions of interest include the gene coding for the d-ALA enzyme that affects lead metabolism and storage (39,43), and a genetic polymorphism in the dopamine transporter that is associated with increased behavioural problems in children prenatally exposed to tobacco smoke (44). Other research has found that the P450 and glutathione-S-transferase gene families play a role in the activation and detoxification of various xenobiotics. They are involved in the metabolism of PAHs and can influence the level of PAH–DNA damage. PAH–DNA adduct levels in human placenta were significantly higher in infants with the *CYP1A1* MspI restriction site, a genetic marker associated with lung cancer risk, than in infants without the restriction site (45). The *GSTT1* genotype was also shown to be a susceptibility marker for lower birth weight and pre-term birth among babies of pregnant women who actively used tobacco (37,46). Children with the *GSTM1* genotype who were exposed *in utero* to tobacco smoke had increased risk for persistent asthma

and wheezing (47,48). The *GSTM1* genotype in asthmatic children is also associated with increased susceptibility to the harmful effects of ozone, such as reduced forced expiratory flow (49).

### **Individual- and community-level psychosocial stressors**

The notion that individual- and community-level conditions can produce profound effects on host susceptibility to disease is derived from the long-standing existence of strong social class gradients in health (50). Recent studies have shown that women who live in violent, crime-ridden, physically decayed neighbourhoods are more likely to experience pregnancy complications and adverse birth outcomes, after adjusting for a range of individual-level sociodemographic attributes and health behaviours (51,52). Other studies have suggested that the stresses of racism and community segregation are associated with lower birth weight (53). The effects of individual poverty on birth outcomes have been shown to be exacerbated by residence in a disadvantaged neighbourhood (54). In one of the few studies that has measured interactions between physical toxicants and individual psychosocial stressors, a prospective cohort study of Northern Manhattan (New York, USA) mothers and toddlers (by the Columbia Center for Children's Environmental Health (CCCEH) cohort) found that the risk of developmental delay among children exposed prenatally to maternal ETS was significantly greater among those whose mothers experienced material hardship during pregnancy (55).

### Examples/case studies: Molecular epidemiology and children's diseases related to environmental factors


The research reviewed in this article is based on the paradigm of a continuum of molecular/genetic alterations between exposure to an external agent and an adverse outcome that can be accessed using biomarkers to provide links in the chain of causality (Figure 26.1). The following is not an encyclopaedic review; rather, examples are provided for illustration of the methodology (Table 26.1).

Based on the growing understanding that children may be more susceptible to toxicants than adults, the last few decades of molecular epidemiologic research have provided a new perspective on studying environmental risks in paediatric populations. As such, the emphasis in conducting studies of disease in children has been placed on identifying less-invasive methods of biological specimen collection; specific approaches to interpretation and validation of biomarkers; methods for translating biomarker results into intervention strategies, and for integrating them with environmental monitoring and health data; optimal ways to obtain consent and provide information to children and/or their parents participating in the studies; and techniques for the effective communication with policy-makers and the public (56).

#### Respiratory disease/asthma

Air pollution and allergens are among the best-studied environmental risk factors, and have been established as important triggers for asthma and respiratory disease in childhood. There appears to be a critical window in both prenatal

Figure 26.1. Molecular epidemiology paradigm. Figure compiled from 136–138



and postnatal development during which exposure to irritants and other toxicants can modify the formation and maturation of the lung, which occurs through years six to eight of life (57). Most of the research on air pollution has focused on the postnatal window of exposure and has not used biomarkers. For example, an association of poorer air quality with increased prevalence of respiratory symptoms in children has been documented in the Netherlands and in Indonesia (58,59). Moreover, increased levels of fine ambient particulate matter have been associated with decreased peak expiratory flow rates among inner-city children with asthma (60). These studies seem to implicate vehicle exhaust emissions and/or ambient particulate matter, especially diesel exhaust particles (DEP) and PAHs, in the exacerbation of asthma. Moreover, a community study of exposure to traffic evaluated 5–7 year old schoolchildren in southern California, USA, and found that residing near a major road was associated with asthma (61). Experimental studies have shown that DEP was associated with a greater risk of becoming sensitized to allergens (62,63). Importantly,

a prospective study in southern California detected significant declines in lung function (FEV1) in association with exposure to nitrogen dioxide, acid vapour, PM<sub>2.5</sub>, and elemental carbon (EC) among children ages 10–18 (64).

The very early causal role of air pollutants in childhood asthma has been less well understood, but has recently benefited from prospective molecular epidemiologic studies that have enrolled pregnant women and assessed *in utero* exposures resulting from the maternal environment. Recent results from such a study in New York City (the CCCEH cohort study) highlight the importance of the prenatal period of development, showing that adaptive immune responses may begin *in utero*, as evidenced by the occurrence of cord blood T-cell proliferation in response to specific allergens, independent of maternal sensitization (65). Moreover, high prenatal exposure to certain airborne PAHs (e.g. pyrene) was found to increase the likelihood of children's allergic response to cockroach, mouse and dust mite allergens as measured by elevated IgE (a biomarker of preclinical effect and a known asthma predictor) at two years of age (66).

Table 26.1. Examples of biomarkers used in children's studies

Type of marker	Biomarker	Sample	Indicator of exposure to	Outcome of concern	Ref
Marker of exposure	S-Phenylmercapturic acid (S-PMA)	Urine	Metabolite of benzene, thought to be derived from the condensation product of benzene oxide with glutathione	Cardiovascular risk (as determined by prevalence of arterial hypertension (AH) and pathologic changes in electrocardiography (ECG))	(128,129)
Internal dose	Levels of 2,2', 4,4', 5,5'-hexachloro-biphenyl (CB-153), as a proxy of the total PCB burden, and of p,p'-DDE	Serum	Persistent organochlorine pollutants, such as polychlorinated biphenyls (PCBs) and dichlorodiphenyldichloroethylene (p,p'-DDE)	Altered sperm DNA/chromatin integrity (i.e. male fertility)	(130)
Internal dose	Newborn cotinine levels (nanograms per milliliter)	Plasma	Active and passive cigarette smoke exposure of the mother	Birth weight and birth length	(131)
Biologically effective dose	PAH-DNA adducts	White blood cells (WBC)	Ambient air pollution (polycyclic aromatic hydrocarbons (PAH), particulate matter, and environmental tobacco smoke (ETS)), which is significantly associated with the amount of PAH bound to DNA	Birth weight, birth length, and head circumference (ultimately, reduction of head circumference at birth correlates with lower intelligence quotient, as well as poorer cognitive functioning and school performance in childhood)	(132)
Preclinical effect	CD4 count	Lymphocytes	HIV virus	HIV-related mortality and time to death, psychological resources (positive affect, positive expectancy regarding health outcomes, finding meaning in challenging circumstances) may be protective	(133)
Clinical disease	Soluble Nogo-A (a development-related molecule inhibiting axonal regeneration) is a major component of central nervous system (CNS) myelin	Cerebrospinal fluid (CSF) and central nervous system (CNS) tissue		Multiple sclerosis (MS) (the etiology of non-reversible neurologic dysfunctions is thought to have something to do with failure of damaged axons to regenerate)	(134)
Individual susceptibility	Polymorphism of enzymes paraoxonase ( <i>PON1</i> ) and glutathione S-transferase ( <i>GSTM1</i> and <i>GSTT1</i> ), which are involved in the detoxification of pesticides	Erythrocytes	Pesticides, including organophosphates and paraquat (exposures to which were evaluated thanks to erythrocyte delta-aminolevulinic acid dehydratase (ALA-D), an important biological indicator of pesticide exposure)	<i>PON1</i> and <i>GSTT1</i> are relevant determinants of susceptibility to chronic pesticide poisoning and pesticide-related symptomatology	(135)

Laboratory studies have suggested possible mechanisms for the effects observed in children. *In vitro* studies have shown that nasal challenges with DEP, combined with ragweed allergen, heightened the production of the Th2 cytokine IL-4 and isotype class switching to IgE (67–69). In addition, DEP has been shown to upregulate the Th2 chemokines, including I-309 and PARC, even among non-atopic subjects (70,71). Combined, these studies suggest that DEP may promote asthma by upregulating IL-4-mediated IgE pathways in response to allergen exposure. DEP exposure has also been shown to increase procollagen gene expression and tissue hydroxyproline levels in explanted rat tracheas (72), which suggests that it may trigger airway remodeling, a pathological phenotype associated with severe asthma (73).

While it is clearly established that ETS exposure is associated with respiratory infections, reduced lung function, and asthma in children (74,75), recent studies suggest that ETS exposure may modulate the respiratory response to other toxic exposures, such as PAHs. There is evidence that cigarette smoke may delay pulmonary clearance of inhaled insoluble particles (76,77). ETS exposure has been shown to exacerbate the IgE-promoting effects of ragweed exposure (78), providing another mechanism whereby ETS can worsen airway disease. In the CCCEH cohort, more cough and wheeze were reported by 12 months of age among children exposed to prenatal PAH in concert with ETS postnatally. By 24 months, difficulty breathing and probable asthma were reported more frequently among children exposed to prenatal PAH and ETS postnatally (66). Most recently, a parallel cohort study in Poland has

assessed PAH exposure during pregnancy by personal air monitors worn by women ( $n = 333$ ) for 48 hours during the second or third trimester of pregnancy. After delivery, the mothers were interviewed every three months over the course of a year. Prenatal PAH exposure was associated independently with an increased risk for respiratory symptoms including wheezing without cold (RR = 3.8; 95% CI = 1.2–12.4) during the course of the infants first year of life (79). The data were adjusted for confounders including ETS, which was verified by cotinine, a biomarker of ETS exposure. These results suggest an independent effect of urban PAH exposure on respiratory outcomes in children (79).

### **Cancer risk/genetic damage**

Environmental exposures are recognized as potentially important risk factors for childhood cancer (80), and again biomarkers are proving useful in assessing causal relationships. For example, carcinogen-DNA adducts are considered a biomarker of the biologically effective dose of PAHs and increased cancer risk (81). Experimental evidence shows that the amount of PAHs crossing the placenta and reaching the fetus is on the order of one-tenth of the dose to the mother (12,13), yet the levels of PAH–DNA adducts measured in rodent fetal tissue are higher than expected based on transplacental dose (14). Similarly, research in mothers and newborns has consistently shown that PAH–DNA adduct levels in the white blood cells (WBC) of newborns were similar to or exceeded those in paired maternal samples, despite the estimated 10-fold lower dose of the parent compound to the fetus (82,83). This research indicates that

the differential effect of exposure to PAHs in the fetus is not limited to a particular ethnic or geographic group (84). Increased adducts in the fetus relative to the adult could result from lower levels of phase II (detoxification) enzymes and decreased DNA repair efficiency in the fetus (19,82,85,86). In addition, fetal plasma cotinine levels were higher than in paired maternal samples, suggesting reduced ability of the fetus to clear carcinogenic cigarette smoke constituents (82,83).

Chromosomal aberrations have been associated with increased risk of cancer in multiple studies, and are a well-validated biomarker of the preclinical effect of carcinogens (87,88). In New York City newborns, maternal exposure to airborne PAHs during pregnancy was associated with increased frequency of chromosomal aberrations in WBCs, suggesting that risk of cancer can be increased by exposure *in utero* (89). Studies have also linked maternal tobacco smoking to increased chromosomal aberrations in the WBCs of newborns (90). Other research has shown an approximately 10-fold higher risk of infant acute myeloid leukaemia (AML) with increasing maternal consumption of DNA topo 2 inhibitor-containing foods, raising concerns about benzene, a topo 2 inhibitor (91).

There is a growing body of evidence from studies of adults that polymorphisms of the DNA repair genes X-ray repair cross-complementing group 1 (*XRCC1*) and xeroderma pigmentosum group D (*XPD*) may constitute susceptibility factors to cancer. The results of a case–control study in a Chinese population suggested that *XRCC1* 194 Trp/Trp and *XPD* 751 Lys allele might be risk genotypes for lung cancer in this population

(92). *XPD* polymorphisms at codons 312 and 751 were both significantly associated with elevated levels of PAH–DNA adducts in tumour tissue from breast cancer cases, suggesting that by increasing DNA damage that may lead to further mutations and contribute to genetic instability in the tumour, *XPD* may play a role in tumour progression (93). While no studies are available in children, it is possible that decreased ability to repair early genetic damage from environmental carcinogens may render children more susceptible to cancer later in life.

Recent reports have established the prenatal origin of leukaemia translocations and resultant fusion genes in some patients, including *MLL-AF4* translocations in infants and *TEL-AML1* translocations in children. Using twins with concordant leukaemia, it was found that a hallmark genetic event in these acute leukemias (i.e. chromosomal translocation) can have a prenatal origin (94–98). More explicit evidence is provided by the finding of clonotypic chromosomal fusion sequences in archived neonatal (Guthrie) heel-prick spots matched to children who later contracted leukaemia (98–100). Additional indirect support for prenatal origin of leukaemia clones is derived from the demonstration of the presence of clonotypic rearrangements at the *IGH* and *TCR* loci in Guthrie spots (101,102).

Furthermore, new evidence for the prenatal origin of a translocation in childhood AML was reported (100). The t(8;21) *AML1-ETO* translocations in childhood AML can arise *in utero*, possibly as an initiating event, and may establish a long-lived or stable parental clone that requires additional secondary genetic alterations to cause leukaemia.

While progress in this field is substantial, a basic understanding of the timing of the origin of the crucial molecular abnormalities, or the natural history of leukaemic clones, is incomplete. The recognition of crucial temporal and developmental windows for the formation of leukemogenic genetic alterations will help to focus epidemiologic analysis as well as to prompt preventive strategies (103).

### Neurobehavioural disorders

The exquisitely sensitive process of the development of the human central nervous system involves the production of 100 billion nerve cells and 1 trillion glial cells, which then must follow a precise stepwise choreography involving migration, synaptogenesis, selective cell loss, and myelination (104). A mistake at any point in the process can have permanent consequences. Experimental studies of prenatal and neonatal exposure to the organophosphate CPF have demonstrated, for example, neurochemical and behavioural effects, as well as selected brain cell loss (105–109). The behavioural and morphologic effects of developmental toxicants are highly dependent on the timing as well as on the dose and duration of exposure. This is illustrated by both rodent and human studies showing that the effect of irradiation on brain malformation is heightened during the window of susceptibility throughout fetal development (104). Adverse neurological development, including lowered intelligence, diminished school performance, and increased rates of behavioural problems have been associated with exposure to low-levels of several environmental toxicants and pollutants.

Cohort studies have demonstrated that low-level exposure to lead (even below 10ug/dL in blood) during early childhood is inversely associated with neuropsychological development through the first 10 years of life (110–114). Prenatal exposure to PCBs and methylmercury, predominantly from maternal seafood consumption, has been associated with neurocognitive deficits (115). In these studies, biomarkers (including levels of blood lead, tooth lead concentrations, blood mercury levels and cord tissue PCB) have been instrumental in quantifying the internal dose of the pollutants. Taking the recent example of pesticides, New York City children in the CCCEH cohort who were prenatally exposed to high levels of CPF, as measured by high cord plasma CPF levels, were significantly more likely than children with low cord levels to experience delay in both psychomotor and cognitive development at three years of age (116). In addition, the highly-exposed children were significantly more likely than less-exposed children to manifest symptoms of attention disorders, attention-deficit/hyperactivity disorder (ADHD) and pervasive personality disorder at age three. Although the EPA banned residential use of CPF in 2001, this pesticide is still widely used in agriculture. In addition, children with high prenatal exposure to airborne PAHs also had significantly lower test scores at age three on the Bayley test for cognitive development, after controlling for pesticide exposure (plasma CPF) (117), and at age 5 had significantly lower IQ (118). Moreover, in the same study, children prenatally exposed to ETS (cotinine-verified), especially children whose mothers experienced material hardship (unmet basic food, clothing and housing needs) had significantly



reduced scores on tests of cognitive development at two years of age (55). Finally, cohort children with high prenatal exposure to PAHs were more likely to experience developmental delays in childhood, after controlling for ETS and CPF (119).

Table 26.1 lists a few hand-picked examples from the literature of biomarkers that have been used to study relationships between exposure and disease in children.

### **Strengths, limitations and lessons learned: Special considerations in mounting children's studies**

Long-term studies that follow participants from the prenatal period into adolescence and early adulthood are considered essential to assess the full range of developmental consequences of exposure to environmental chemicals. (The advantages of prospective cohort studies and their logistical, ethical, and financial challenges are discussed in Chapter 17.)

To address some of the important lessons from prior research regarding the logistics, ethics, and the financing of these long-term studies in children, the platform in which many of these challenges were encountered, tackled and, for the most part, overcome is introduced.

### **National centers for children's environmental health**

In 1998, the US National Institute of Environmental Health Sciences (NIEHS) and the EPA collaborated to develop a research programme (the Children's Centers) that would coordinate efforts to better understand toxic exposures to infants and young children, study

the health effects of such exposures to clarify the mechanisms by which they work, and explore intervention strategies for reducing such exposures in a way that would provide evidence for practice. Each centre is designed around a central theme focusing on important questions regarding the role of exposures in one of the following health outcome areas: respiratory disease, childhood learning, and growth and development, including developmental disabilities. The purpose of the Children's Centers programme was to create local research environments that promote multidisciplinary interactions among basic, clinical and behavioural scientists through university/community partnering, to accelerate translation of basic research findings into clinical prevention or intervention strategies. Additionally, it was designed to support a coordinated, nationwide network of scientists and community advocacy groups synergistically sharing their experiences to address relevant questions related to the role of environmental exposures in the health of children, to enhance community-level capacity to identify and address environmental threats and prevention opportunities (120). (A full description of the Children's Centers can be found on the NIEHS web site (121), and a summary of the first eight centres has been more fully discussed by (122) and (123).)

The Children's Centers have addressed and overcome many hurdles in their efforts to understand the link between environmental exposures and health outcomes, as well as interactions between exposures, and a variety of social and cultural factors. Out of their enterprise, several lessons have been learned on the practicalities of conducting longitudinal birth cohorts, such as the critical

importance of long-term studies for assessing the full range of developmental consequences of environmental exposures, recognition of the unique challenges presented at different life stages for both outcome and exposure measurement, and the importance of ethical issues that must be dealt with in a changing medical and legal environment (120). In the following section, some of the more specific shared experiences are paraphrased as they pertain to the methodological, logistical, ethical and communication issues (124).

### **Successes, challenges and lessons learned**

#### *Logistical issues in children's studies*

**Barriers to recruitment.** The most common and important barriers to recruitment into prospective cohort studies, especially for working women, is the time required for each visit and the length of the follow-up period. Many members of a population are also distrustful of Western medicine and research. Solutions to these obstacles include hiring study staff familiar with or from the target population, recruitment by or at clinics known by the community to respect patient confidentiality, and allowing time for potential participants to discuss the study with their families before enrolment.

**Staffing issues.** Building trusting relationships with participants in the cohort is best accomplished by hiring bilingual, bicultural staff from the local community, who are assigned to follow particular families ideally from pregnancy through the child's assessments. Although this is helpful, it can introduce systematic bias. Often, more in-depth training on data collection

techniques is needed than when hiring from within the academic community. In addition, the number of staff required to maintain a birth cohort, which includes conducting weekday, weeknight and weekend assessments, as well as completing quality control tasks, is often much larger than projected. Gaps in funding are extremely detrimental.

**Retention.** Besides the decrease in cohort size, one of the main issues with retention of participants is that loss to follow-up often differs from continuing participants with some demographic characteristics, such as age, marital status, medical insurance status, race and ethnicity. The most common reason for attrition is the inability to locate participants due to disconnected phones and/or frequent moves, regularly missed appointments leading to exclusion from the study, refusal to continue, or in a few cases, infant deaths. Different incentives that have been successful in improving retention rates include payments, often times incremental over the course of enrolment, gift certificates (e.g. to grocery stores), and bonus incentives for certain activities (e.g. calling study staff when in labour, returning on a separate day to finish an assessment or provide an additional sample, or providing new contact information upon moving). Incentives remain a major budget item to be considered in the planning stages of such a study. Maintaining contact every few months with birthday cards, brief telephone interviews about the child's health, or simple check-ins with the family to remind them of the next phases of the study, is also critical.

**Environmental assessments.** Home inspections to assess housing quality are time-consuming and require extensive training. It might be necessary to visit homes multiple times to reassess

household exposures, which may vary by season or change when families relocate (125). Collecting environmental measurements often requires the purchase of expensive, specialized collection equipment (e.g. air monitors) and a delay between home assessments to allow for cleaning of equipment. In addition, standard practices for interpreting ambient measurements are not yet fully developed; for example, it is unclear for most contaminants whether house dust concentration ( $\mu\text{g}$  per gram of dust) or loading ( $\mu\text{g}$  of surface area) is a better predictor of children's exposure or body burden.

**Delivery events.** Shortened post-delivery hospital stays in the United States leave a limited window of opportunity to collect information and samples from mothers and neonates in the hospital. Because of the slow notification of participants' admission for delivery, a large proportion of women fail to be tracked at the time of delivery. For efficient notification, researchers must rely on both participating women and delivery ward staff. Some of the solutions developed by researchers include: distributing cell phones to enable mothers without home phones to call the research team, or alternatively, distributing t-shirts or socks to wear to the hospital, which will alert the delivery staff; providing lists of participants approaching their due date to medical stations; and checking delivery logbooks daily. Cord blood samples are particularly difficult to obtain. Most missed collections occur when women's delivery admissions are not reported to research staff; additional samples are missed from high-risk children with emergency deliveries. The greatest collection rate tends to be reported by the research teams that involve physicians in collecting

the samples. Conducting neonatal assessments is also a difficult task. Few tests are available to assess newborn behaviour, and their predictive validity is not high. Many assessment tests require trained evaluators, who are not easily replaced when they leave projects, which can create gaps in cohort assessment. Within the context of shortened post-delivery hospital stays, post-delivery assessments have to be scheduled both after the effects of delivery medications wear off, and between the child's sleeping and eating schedule. Finding a quiet assessment room in the hospital can also be a challenge. Due to these various impediments, assessments intended for the neonatal period are in many cases conducted several weeks after delivery. Early-morning assessments and assessment of the child both soon after delivery and again one month later tend to increase success with hospital assessments.

**Child assessments.** Conducting assessments on small children in the home is nearly impossible, thus the provision of a standardized testing facility may be essential. Minimizing distractions to children during neurobehavioural assessment is particularly challenging. For children > 12 months of age, it is desirable to assess the child separately from the mother to reduce interference; this requires additional time for the tester to build a rapport with the child. Siblings can also be a source of distraction during assessments. On-site childcare, giving reimbursements for off-site childcare, and/or using videos or games to busy these children are some handy options; however, the ideal arrangement is on-site childcare with dedicated space and personnel.

**Problems in sample collection.** Blood collection from children is a challenge. Collecting research

blood samples at the same time as clinical samples helps to avoid participant concerns about taking blood from children and pregnant women, especially in certain cultural groups. Consulting with community physicians to determine the amount of blood collection that is both clinically and culturally acceptable to the target population is also helpful. Collecting breast milk samples soon after delivery, although most convenient for the research team, can be daunting for mothers, as the milk supply may not yet be fully developed. Later collection of breast milk avoids some of these problems, but timing issues may arise for other sample types as well. Studies conducted in rural areas face additional barriers to successful collection and processing of samples, such as limited laboratory facilities that are not adequately equipped to process samples (e.g. to separate whole blood into blood products). In this case, it is necessary to transport samples over long distances, which increases costs. In locations where necessary goods and services (e.g. dry ice or courier services) are in short supply, it can also be difficult to ensure the prompt stabilization of samples. Finally, some rural areas may lack skilled paediatric phlebotomists.

**Participant fatigue.** Longitudinal studies are demanding for families. To minimize participant fatigue, researchers should aim to optimize contact frequency such that attrition is prevented, but participants are not overly burdened. It is important to design contact between researchers and study participants to be as brief and efficient as possible; respect for participants' time may require that the focus of research be narrowed down. Strategies employed to minimize the impact of participant fatigue include using

multiple workers to simultaneously collect information at each visit. This requires that each research worker is trained in multiple aspects of the study protocol (sometimes though, multiple short visits were preferred to one long visit, both for convenience and to prevent child fatigue). Other approaches were to provide snacks in case of lengthy and demanding assessments; develop qualitative assessments that allowed study staff to document participants' level of fatigue, cooperation, and attention; and to record any changes made to the usual study protocol.

**Quality control of assessments and interviews.** Proper staff training is critical. Adequate pilot testing is important, but often hindered by time, cost and the need for prior Institutional Review Board (IRB) approval. Insufficient time and resources are the main reasons why clear quality control protocols (e.g. direct observation, review of videotapes by the other evaluators and lead psychologists) fall short. Even after extensive staff training, inter-rater differences and reliability issues also remain a concern.

**Lack of transportation.** Transportation can be a barrier to successful completion of assessments. Paying for taxi services, reimbursing participants for alternate travel costs, transporting participants to the office for an assessment after completing a home visit, purchasing and outfitting an RV that could be driven to participants' homes and used as a roving assessment room, or simply purchasing a car for the study to reduce mileage reimbursement costs and wear and tear on staff cars, are a few of the solutions to which Children's Centers have turned to address this problem.

**Issues of literacy, language and culture.** The wording and phrasing of all study documents,

including consent forms, must be simple; in addition, most study instruments, including those designed for self-administration, must be administered orally to attend to the issue of participants with limited education and low literacy. Potentially embarrassing topics that evade translation (e.g. specific birth control methods) may have to be described graphically. Other culturally sensitive issues to be attentive to include participants not knowing or not sharing their exact date of birth, being hesitant to provide biologic samples, and reporting pregnancy relatively late in gestation. Understanding these types of issues and planning the research accordingly relies heavily on focus groups with community members. Because young children cannot precisely answer questionnaires regarding behaviour or habits, researchers must often ask the child's mother for a specific answer in a follow-up.

In terms of the logistics of a longitudinal birth cohort study, it is critical that funding be adequate for the start-up period, continuous without gaps, and extend for the long-term. Costs are often underestimated for labour intensive activities, such as tracking and maintaining study participants.

### *Ethical issues*

The ethical issues in a longitudinal birth cohort study are likely to become increasingly more complex in the changing medical and legal environment, and must be carefully considered in designing research protocols and following the cohort. It is particularly necessary to develop clear plans of referral when children with disease, developmental difficulties, or adverse social situations emerge.

Increasing ethical complexity. Since the implementation of the Health Insurance Portability and Accountability Act (HIPAA), it has become more time-consuming to obtain participants' informed consent for studies in the USA. Concerns about potential lawsuits have increased, and conflicting ethical issues are routine (e.g. deciding when the health and safety of a child takes precedence over a promise of confidentiality).

Consent and assent. Because longitudinal studies demand lengthy and complex consent forms, ensuring that participants are well informed is challenging and requires the allocation of adequate time and resources. For studies using medical records in the USA, the completion of HIPAA subject authorization forms adds time to the consent process. It has been found to be important to inculcate in staff an understanding that consent is an ongoing process; instead of training staff to simply procure participant signatures, centres have trained staff to solicit and answer participants' questions so that they can make informed decisions. Clearly, writing consent forms at a reading level understandable to all is critical. In cases where the level is suspected to be too high to assure comprehension, research workers have the option of reading consent forms aloud to participants to ensure that everyone, including participants who are embarrassed to admit their low literacy level, fully understands the information. Solicited feedback from community partners, community board members and community-based staff (in addition to the IRB) also helps ensure that appropriate language is used. Additional measures to enhance understanding of consent forms include providing study participants with timetables and schedules to

communicate study procedures, or lists outlining the important items on the consent. Providing short checklists to verify that participants understand the key aspects of the study is also effective. All solutions that decrease the amount of complex information that participants have to digest at each visit and give them an opportunity to re-evaluate their participation at a midway point are helpful. While studies often operate with uncertainty about funding and the future direction in the long run, continuing requests for participation can be a source of frustration; full disclosure of the protocol up-front is thus preferable. Careful thought must be given to *who* must consent to participate at each stage of the research. In all cases, a pregnant woman or mother should be asked to consent to her own participation and that of her child. However, once children reach a certain age (generally 5–9 years), child assent is typically also required by the IRB, leading to new challenges.

Banked samples and informed consent. The process of banking samples for future studies requires special consideration, as participants must be informed about and consent to future uses of these samples. Consent forms may allow participants the option of either not having samples banked and/or not allowing future analysis of samples for unrelated studies. IRB re-approvals may additionally be required for each new analysis of banked samples.

Confidentiality and consideration of children at risk. Protecting the identity and personal information of all participants can be difficult in small or close-knit communities, especially when the research staff was hired from the local community.

Confidentiality within computerized databases also requires particular attention. All computerized files should be

password-protected with knowledge of passwords restricted to a small number of staff. The number of computer or paper files containing both the participant study number and identifying information (e.g. name) should be limited. In complex studies with multiple contacts, it can be necessary to work with both the IRB and the research staff to identify the types of linked information necessary for day-to-day operations, and to provide that information with the least possible risk to participants.

Protocols on intervening in cases of clear developmental delays or undiagnosed physical health problems are compulsory. Most protocols include timely screening of developmental assessments and questionnaires to ensure prompt referral or treatment. Reporting some exposure measures, such as lead results, to public health authorities when they exceed certain action levels is also essential. Lastly, certificates of confidentiality, which protect identifiable research information from forced disclosure, including in the case of legal action, are an important component in protecting participant confidentiality. However, an investigator might need to break the promise of confidentiality without participant consent, for example, in cases where child abuse, severe depression, drug use or traffic in the home, and other potentially dangerous conditions are observed. Disclosure of such requirements (e.g. the need to report child abuse) is typically incorporated into consent forms, despite concern that it would deter some participants.

### *Communication issues*

Communicating study results is a key step in any research project. In addition to publishing results

in scientific journals, centres should seek to share findings with participants and community members. Researchers may benefit from soliciting the guidance of community collaborators to decide when and how to disseminate results, including how to clearly craft messages so they would be understood and of interest to the community. In some cases, communities expect interventions and actions that are outside the scope of the research; therefore it is important to concisely communicate the purposes and limitations of the research beforehand to prevent false expectations.

Timing of the results communication. It is advisable to disclose findings to participants and/or community advisory boards before their publication in journal or newspaper articles. This disclosure is an important step in building trust between researchers, participants, and communities. Community members resent hearing findings for the first time in the media.

Communication tools. Strategies to disseminate information, developed in collaboration with community advisory boards, have included newsletters, fact sheets, pamphlets, press releases in local papers, pay-stub inserts, radio programmes (particularly useful in rural areas), town hall meetings, and internet sites. Ideally, researchers concerned with children's health would also like to communicate results to children themselves. Based on results from their study of pesticide exposure in children, the University of Washington's Center for Children's Environmental Health (Center for Child Environmental Health Risk Research) created colouring books and curricula to educate preschool and school-age children on how to prevent exposure to pesticides. Specialized tools are

sometimes needed for studies that target low-literacy or non-majority-language-speaking communities. Publishing information in more than one language is essential, and successful attempts to develop pictorial rather than verbal messages have also been made (126) ([http://www.checnet.org/healthhouse/education/articles-detail.asp?Main\\_ID=644](http://www.checnet.org/healthhouse/education/articles-detail.asp?Main_ID=644)).

Group- versus individual-level results. Perhaps the biggest communication issue has to do with whether to provide individual-level results, particularly for measures of exposure or internal dose. The argument in favour of providing such results is that participants have the right to know; the counterargument is that participants may be unnecessarily alarmed by results with no interpretable meaning. Generally, results with a clear clinical implication (e.g. blood lead levels) have been reported to participants, whereas results without clear clinical implications (e.g. urinary pesticide metabolite levels) have not been shared. One centre, however, on the basis of community advisory board input, decided to offer participants the option of requesting their individual pesticide levels. That centre is currently in the process of developing materials to provide these results and will work closely with community health care providers when clinical questions arise (124). Regardless of whether group- or individual-level results are returned, it is important to provide participants a context for these results. Providing a comparison, either to other study participants or nationwide data, has been particularly helpful. In communicating results, centres aim to clearly describe their implications for health and well-being; when these implications are not known (as in the case of pesticides), centres state this honestly (104).

Active and meaningful participation of the community is essential for determining the relevant research questions, enrolling and retaining the cohort in an intensive investigation over the long term, and contributing to translation of scientific principles and research results for communities and the public at large. This requires establishing trust and respecting differences in culture and knowledge of the community. Sufficient time and resources are necessary to develop community partnerships.

## Future directions and challenges: Looking ahead

### Summary

Recent molecular epidemiologic research has helped identify etiologic factors in childhood diseases. Exposures of particular concern for the fetus and young child are environmental tobacco smoke (ETS); polycyclic aromatic hydrocarbons (PAHs); particulate matter; nitrosamines; pesticides; polychlorinated biphenyls (PCBs); metals and radiation, which may be involved in respiratory disease and asthma; cancer risk and genetic damage; and neurobehavioural disorders. Molecular epidemiology has also been a useful tool in identifying the interactions between exposures and certain "host" factors, such as genetic susceptibility, nutritional deficits, and psychosocial stressors that can lead to disease. It has also provided compelling new evidence that early exposure to environmental factors is a likely contributor to disease in later years of life.

The powerful need for prevention, as directed by current trends in disease incidence, requires that strong, collaborative research be performed, especially

on populations most at risk. The logistics involved in designing and conducting such observational research, adequate communication of the research findings to populations enrolled in the study, as well as the ethics at stake, present real challenges. Strategies for conducting cutting-edge yet safe and responsible research must therefore be widely shared and understood.

### **Future directions: Suggestions**

#### *New epigenetic and “omic” biomarkers*

The previous generation of biomarkers has contributed to our understanding of risk and susceptibility related to genotoxic carcinogens. As a result, interventions and policy changes have been mounted to reduce risk to children from several important environmental carcinogens. More recently developed biomarkers have considerable potential in molecular epidemiology, as they reflect another equally important mechanism of carcinogenicity: epigenetic alterations that affect the expression of genes and proteins. These can be measured by high-throughput methods, allowing large-scale studies that are ‘discovery-oriented.’ Research using these techniques is needed to study the effects of multiple exposures and their interactions both with each other and in combination with different types of susceptibility factors. Gene–environment interactions should be a major focus, but interactions with nutritional and psychosocial factors also deserve emphasis in

future research. Studying the low-level exposure effects of global pollutants and their interactions with susceptibility factors in different geographic locations, exposure scenarios, and ethnic/racial groups will help in understanding etiology and confirm findings. However, most of these markers have not yet been validated, and their role in the causal paradigm is not clear. There is an urgent need for validation of these newer biomarkers so that they can be combined with the more traditional ones in hypothesis-testing studies. Large-scale, long-term prospective studies will be the key to achieving this.

#### *National Children’s Study*

In the USA, studies under way at the National Centers for Children’s Environmental Health were among the first in line to meet these needs. The National Children’s Study (NCS) (a programme that will follow 100 000 children across the US from before birth until age 21) will examine the effects of natural and man-made environment factors, biological and chemical factors, physical surroundings, social factors, behavioural influences and outcomes, genetics, cultural and family differences, and geographic location on the health and development of children in the cohort (127). (A summary of the participating cohorts and links to their web pages, as well as links to updates on the NCS, can be found at: <http://www.nationalchildrensstudy.gov/studylocations/Pages/websites.aspx>.)

### **Conclusion**

Molecular epidemiology has contributed much to our knowledge of risk factors for environmental health-related diseases in children. The high rates of asthma, certain cancers and developmental disabilities, and the growing evidence that risk of certain adult diseases is associated with *in utero* and childhood exposures, indicate that maintaining an early focus in molecular epidemiology can have a significant impact on the overall burden of disease. When preventive measures have been enacted based on this knowledge in the past, children’s health has benefited. Incorporating strategic principles to translate existing and future data into public health policy will ensure benefits in children’s environmental health.

### **Acknowledgements**

This work has been made possible by the following NIEHS grants: 5P01ES09600, R01ES09089, 5R01ES101654, and by the Harriman Foundation and the New York City Community Trust.

# References

1. Woodruff TJ, Axelrad DA, Kyle AD *et al.* America's children and the environment: measures of contaminants, body burdens, and illnesses. Washington (DC): U.S. Environmental Protection Agency; 2003.
2. Dey AN, Bloom B. Summary health statistics for U.S. children: National Health Interview Survey, 2003. *Vital Health Stat* 2005;223(Series 10):1–78.
3. Nicholas SW, Jean-Louis B, Ortiz B *et al.* (2005). Addressing the childhood asthma crisis in Harlem: the Harlem Children's Zone Asthma Initiative. *Am J Public Health*, 95:245–249. doi:10.2105/AJPH.2004.042705 PMID:15671459
4. Ries LAG, Smith MA, Gurney JG *et al.*, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995, National Cancer Institute. NIH Publication No. 99–4649. Bethesda, MD, 1999.
5. Kaatsch P (2010). Epidemiology of childhood cancer. *Cancer Treat Rev*, 36: 277–285. doi:10.1016/j.ctrv.2010.02.003 PMID:20231056
6. Boyle CA, Decouflé P, Yeargin-Allsopp M (1994). Prevalence and health impact of developmental disabilities in US children. *Pediatrics*, 93:399–403. PMID:7509480
7. Grandjean P, Landrigan PJ (2006). Developmental neurotoxicity of industrial chemicals. *Lancet*, 368:2167–2178. doi:10.1016/S0140-6736(06)69665-7 PMID:17174709
8. U.S. Environmental Protection Agency. Chemical hazard data availability study. Washington (DC): U.S. Environmental Protection Agency; 1998.
9. U.S. Environmental Protection Agency. Proposed guidelines for carcinogen risk assessment. Washington (DC): Office of Research and Development; 1996.
10. Birnbaum LS, Fenton SE (2003). Cancer and developmental exposure to endocrine disruptors. *Environ Health Perspect*, 111:389–394. doi:10.1289/ehp.5686 PMID:12676588
11. Perera FP, Illman SM, Kinney PL *et al.* (2002). The challenge of preventing environmentally related disease in young children: community-based research in New York City. *Environ Health Perspect*, 110:197–204. doi:10.1289/ehp.02110197 PMID:11836150
12. Srivastava VK, Chauhan SS, Srivastava PK *et al.* (1986). Fetal translocation and metabolism of PAH obtained from coal fly ash given intratracheally to pregnant rats. *J Toxicol Environ Health*, 18:459–469. doi:10.1080/15287398609530885 PMID:3712502
13. Neubert D, Tapken S (1988). Transfer of benzo(a)pyrene into mouse embryos and fetuses. *Arch Toxicol*, 62:236–239. doi:10.1007/BF00570149 PMID:3196162
14. Lu LJ, Disher RM, Reddy MV, Randerath K (1986). 32P-postlabeling assay in mice of transplacental DNA damage induced by the environmental carcinogens safrole, 4-aminobiphenyl, and benzo(a)pyrene. *Cancer Res*, 46:3046–3054. PMID:3698023
15. Lu LJ, Wang MY (1990). Modulation of benzo(a)pyrene-induced covalent DNA modifications in adult and fetal mouse tissues by gestation stage. *Carcinogenesis*, 11:1367–1372. doi:10.1093/carcin/11.8.1367 PMID:2387022
16. Bearer CF (1995). Environmental health hazards: how children are different from adults. *Future Child*, 5:11–26. doi:10.2307/1602354 PMID:8528683
17. Wiles R, Campbell C. Pesticides in children's food. Washington (DC): Environmental Working Group; 1993.
18. International Programme on Chemical Safety Commission of the European Communities. Principles for evaluating health risks from chemicals during infancy and early childhood: the need for a special approach. Environmental Health Criteria. 59<sup>th</sup> ed. Geneva (Switzerland): World Health Organization; 1986.
19. National Research Council. Pesticides in the diets of infants and children. Washington (DC): National Academy Press, 1993.
20. Sonawane B, Beliles R. The susceptibility of children to immunotoxic and neurotoxic agents. Poster Abstract, 1<sup>st</sup> National Research Conference on Children's Environmental Health, Children's Environmental Health Network, February 21–23, 1997, Washington (DC); 1997.
21. Perera FP (1996). Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. *J Natl Cancer Inst*, 88:496–509. doi:10.1093/jnci/88.8.496 PMID:8606378
22. National Research Council. Toxicological effects of methylmercury. Washington (DC): National Academy Press; 2000.
23. Ramirez GB, Cruz MC, Pagulayan O *et al.* (2000). The Tagum study I: analysis and clinical correlates of mercury in maternal and cord blood, breast milk, meconium, and infants' hair. *Pediatrics*, 106:774–781. doi:10.1542/peds.106.4.774 PMID:11015522
24. Perera FP, Tang D, Whyatt R *et al.* (2005). DNA damage from polycyclic aromatic hydrocarbons measured by benzo(a)pyrene-DNA adducts in mothers and newborns from Northern Manhattan, the World Trade Center Area, Poland, and China. *Cancer Epidemiol Biomarkers Prev*, 14:709–714. doi:10.1158/1055-9965.EPI-04-0457 PMID:15767354
25. Furlong CE, Holland N, Richter RJ *et al.* (2006). PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. *Pharmacogenet Genomics*, 16:183–190. PMID:16495777
26. Hales CN, Barker DJ (1992). Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia*, 35:595–601. doi:10.1007/BF00400248 PMID:1644236
27. Bateson P, Martin P. Design for a life: how behaviour develops. London (U.K.): Jonathan Cape; 1999.
28. Robinson R (2001). The fetal origins of adult disease. *BMJ*, 322:375–376. doi:10.1136/bmj.322.7283.375 PMID:11179140
29. Barker DJP. Mothers, babies and health in later life. 2<sup>nd</sup> ed. Edinburgh (U.K.): Churchill Livingstone; 1998.
30. Crawford MA, Doyle W, Drury P *et al.* (1989). n-6 and n-3 fatty acids during early human development. *J Intern Med Suppl*, 731 Suppl 1:159–169. PMID:2706039
31. Voigt RG, Jensen CL, Fraley JK *et al.* (2002). Relationship between omega3 long-chain polyunsaturated fatty acid status during early infancy and neurodevelopmental status at 1 year of age. *J Hum Nutr Diet*, 15:111–120. doi:10.1046/j.1365-277X.2002.00341.x PMID:11972740
32. Makrides M, Neumann M, Simmer K *et al.* (1995). Are long-chain polyunsaturated fatty acids essential nutrients in infancy? *Lancet*, 345:1463–1468. doi:10.1016/S0140-6736(95)91035-2 PMID:7769900
33. Hatch GE (1995). Asthma, inhaled oxidants, and dietary antioxidants. *Am J Clin Nutr*, 61 Suppl:625S–630S. PMID:7879729
34. Greene LS (1995). Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. *J Am Coll Nutr*, 14:317–324. PMID:8568107
35. Peat JK, Britton WJ, Salome CM, Woolcock AJ (1987). Bronchial hyperresponsiveness in two populations of Australian schoolchildren. III. Effect of exposure to environmental allergens. *Clin Allergy*, 17:291–300. doi:10.1111/j.1365-2222.1987.tb02017.x PMID:3621548

36. Perera FP, Whyatt RM, Jedrychowski W *et al.* (1998). Recent developments in molecular epidemiology: A study of the effects of environmental polycyclic aromatic hydrocarbons on birth outcomes in Poland. *Am J Epidemiol*, 147:309–314. PMID:9482506
37. Wang X, Zuckerman B, Pearson C *et al.* (2002). Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. *JAMA*, 287:195–202. doi:10.1001/jama.287.2.195 PMID:11779261
38. Mutch E, Blain PG, Williams FM (1992). Interindividual variations in enzymes controlling organophosphate toxicity in man. *Hum Exp Toxicol*, 11:109–116. doi:10.1177/096032719201100209 PMID:1349216
39. Greater Boston Physicians for Social Responsibility. In harm's way: toxic threats to child development. Cambridge (MA): Greater Boston Physicians for Social Responsibility; 2000.
40. Costa LG, Cole TB, Vitalone A, Furlong CE (2005). Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. *Clin Chim Acta*, 352:37–47. doi:10.1016/j.cccn.2004.09.019 PMID:15653099
41. Costa LG (2006). Current issues in organophosphate toxicology. *Clin Chim Acta*, 366:1–13. doi:10.1016/j.cca.2005.10.008 PMID:16337171
42. Berkowitz GS, Wetmur JG, Birman-Deych E *et al.* (2004). In utero pesticide exposure, maternal paraoxonase activity, and head circumference. *Environ Health Perspect*, 112:388–391. doi:10.1289/ehp.6414 PMID:14998758
43. Shen XM, Wu SH, Yan CH *et al.* (2001). Delta-aminolevulinatase polymorphism and blood lead levels in Chinese children. *Environ Res*, 85:185–190. doi:10.1006/enrs.2000.4230 PMID:11237505
44. Kahn RS, Khoury J, Nichols WC, Lanphear BP (2003). Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. *J Pediatr*, 143:104–110. doi:10.1016/S0022-3476(03)002087 PMID:12915833
45. Whyatt RM, Bell DA, Jedrychowski W *et al.* (1998). Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype. *Carcinogenesis*, 19:1389–1392. doi:10.1093/carcin/19.8.1389 PMID:9744534
46. Delpisheh A, Brabin L, Topping J *et al.* (2009). A case-control study of CYP1A1, GSTT1 and GSTM1 gene polymorphisms, pregnancy smoking and fetal growth restriction. *Eur J Obstet Gynecol Reprod Biol*, 143:38–42. doi:10.1016/j.ejogrb.2008.11.006 PMID:19147266
47. Gilliland FD, Li YF, Gong H Jr, Diaz-Sanchez D (2006). Glutathione S-transferases M1 and P1 prevent aggravation of allergic responses by secondhand smoke. *Am J Respir Crit Care Med*, 174:1335–1341. doi:10.1164/rccm.200509-1424OC PMID:17023730
48. Rogers AJ, Brasch-Andersen C, Ionita-Laza I *et al.* (2009). The interaction of glutathione S-transferase M1-null variants with tobacco smoke exposure and the development of childhood asthma. *Clin Exp Allergy*, 39:1721–1729. doi:10.1111/j.1365-2222.2009.03372.x PMID:19860819
49. Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M *et al.* (2004). Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. *Thorax*, 59:8–10. PMID:14694237
50. Cassel J (1976). The contribution of the social environment to host resistance: the Fourth Wade Hampton Frost Lecture. *Am J Epidemiol*, 104:107–123. PMID:782233
51. Zapata BC, Rebolledo A, Atalah E *et al.* (1992). The influence of social and political violence on the risk of pregnancy complications. *Am J Public Health*, 82:685–690. doi:10.2105/AJPH.82.5.685 PMID:1566947
52. Kliegman RM (1992). Perpetual poverty: child health and the underclass. *Pediatrics*, 89:710–713. PMID:1557266
53. David RJ, Collins JW Jr (1997). Differing birth weight among infants of U.S.-born blacks, African-born blacks, and U.S.-born whites. *N Engl J Med*, 337:1209–1214. doi:10.1056/NEJM199710233371706 PMID:9337381
54. Wise PH (1993). Confronting racial disparities in infant mortality: reconciling science and politics. *Am J Prev Med*, 9 Suppl:7–16. PMID:8123287
55. Rauh VA, Whyatt RM, Garfinkel R *et al.* (2004). Developmental effects of exposure to environmental tobacco smoke and material hardship among inner-city children. *Neurotoxicol Teratol*, 26:373–385. doi:10.1016/j.nt.2004.01.002 PMID:15113599
56. Neri M, Ugolini D, Bonassi S *et al.* (2006). Children's exposure to environmental pollutants and biomarkers of genetic damage. II. Results of a comprehensive literature search and meta-analysis. *Mutat Res*, 612:14–39. doi:10.1016/j.mrrev.2005.04.003 PMID:16027031
57. Plopper CG, Fanucchi MV (2000). Do urban environmental pollutants exacerbate childhood lung diseases? *Environ Health Perspect*, 108:A252–A253. doi:10.1289/ehp.108-a252 PMID:10856036
58. Hong CY, Chia SE, Widjaja D *et al.* (2004). Prevalence of respiratory symptoms in children and air quality by village in rural Indonesia. *J Occup Environ Med*, 46:1174–1179. doi:10.1097/01.jom.0000141666.21758.86 PMID:15534505
59. Janssen NA, Brunekreef B, van Vliet P *et al.* (2003). The relationship between air pollution from heavy traffic and allergic sensitization, bronchial hyperresponsiveness, and respiratory symptoms in Dutch schoolchildren. *Environ Health Perspect*, 111:1512–1518. doi:10.1289/ehp.6243 PMID:12948892
60. Mortimer KM, Neas LM, Dockery DW *et al.* (2002). The effect of air pollution on inner-city children with asthma. *Eur Respir J*, 19:699–705. doi:10.1183/09031936.02.00247102 PMID:11999000
61. McConnell R, Berhane K, Yao L *et al.* (2006). Traffic, susceptibility, and childhood asthma. *Environ Health Perspect*, 114:766–772. doi:10.1289/ehp.8594 PMID:16675435
62. Diaz-Sanchez D, Tsieng A, Fleming J, Saxon A (1997). Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human in vivo nasal ragweed-specific IgE and skews cytokine production to a T helper cell 2-type pattern. *J Immunol*, 158:2406–2413. PMID:9036991
63. Wyler C, Braun-Fahrlander C, Kunzli N *et al.*; The Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team (2000). Exposure to motor vehicle traffic and allergic sensitization. *Epidemiology*, 11:450–456. doi:10.1097/00001648-200007000-00015 PMID:10874554
64. Gauderman WJ, Avol E, Gilliland F *et al.* (2004). The effect of air pollution on lung development from 10 to 18 years of age. *N Engl J Med*, 351:1057–1067. doi:10.1056/NEJMoa040610 PMID:15356303
65. Miller RL, Chew GL, Bell CA *et al.* (2001). Prenatal exposure, maternal sensitization, and sensitization in utero to indoor allergens in an inner-city cohort. *Am J Respir Crit Care Med*, 164:995–1001. PMID:11587985
66. Miller RL, Garfinkel R, Horton M *et al.* (2004). Polycyclic aromatic hydrocarbons, environmental tobacco smoke, and respiratory symptoms in an inner-city birth cohort. *Chest*, 126:1071–1078. doi:10.1378/chest.126.4.1071 PMID:15486366
67. U.S. Environmental Protection Agency. Health assessment document for diesel engine exhaust. Available from URL: <http://www.epa.gov/fedrgstr/EPA-AIR/2002/September/Day-03/a22368.htm> 2002;67(170).
68. Devouassoux G, Saxon A, Metcalfe DD *et al.* (2002). Chemical constituents of diesel exhaust particles induce IL-4 production and histamine release by human basophils. *J Allergy Clin Immunol*, 109:847–853. doi:10.1016/j.jaci.2002.12.2843 PMID:11994710
69. Fujieda S, Diaz-Sanchez D, Saxon A (1998). Combined nasal challenge with diesel exhaust particles and allergen induces in vivo IgE isotype switching. *Am J Respir Cell Mol Biol*, 19:507–512. PMID:9730879
70. Chang Y, Sénéchal S, de Nadai P *et al.* (2006). Diesel exhaust exposure favors TH2 cell recruitment in nonatopic subjects by differentially regulating chemokine production. *J Allergy Clin Immunol*, 118:354–360. doi:10.1016/j.jaci.2006.04.050 PMID:16890758



71. Sénéchal S, de Nadai P, Ralainirina N *et al.* (2003). Effect of diesel on chemokines and chemokine receptors involved in helper T cell type 1/type 2 recruitment in patients with asthma. *Am J Respir Crit Care Med*, 168:215–221. doi:10.1164/rccm.200211-1289OC PMID:12724126
72. Dai J, Xie C, Vincent R, Churg A (2003). Air pollution particles produce airway wall remodeling in rat tracheal explants. *Am J Respir Cell Mol Biol*, 29:352–358. doi:10.1165/rcmb.2002-0318OC PMID:12649123
73. Ohta K, Yamashita N, Tajima M *et al.* (1999). Diesel exhaust particulate induces airway hyperresponsiveness in a murine model: essential role of GM-CSF. *J Allergy Clin Immunol*, 104:1024–1030. doi:10.1016/S0091-6749(99)70084-9 PMID:10550748
74. U.S. Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. Washington (DC): Office of Health and Environmental Assessment, Office of Research and Development; 1992.
75. Pinkerton KE, Joad JP (2000). The mammalian respiratory system and critical windows of exposure for children's health. *Environ Health Perspect*, 108 Suppl 3:457–462. doi:10.2307/3454537 PMID:10852845
76. Bohning DE, Atkins HL, Cohn SH (1982). Long-term particle clearance in man: normal and impaired. *Ann Occup Hyg*, 26:259–271. doi:10.1093/annhyg/26.2.259 PMID:7181269
77. Finkelstein JN, Johnston CJ (2004). Enhanced sensitivity of the postnatal lung to environmental insults and oxidant stress. *Pediatrics*, 113 Suppl:1092–1096. PMID:15060204
78. Diaz-Sanchez D, Rumold R, Gong H Jr (2006). Challenge with environmental tobacco smoke exacerbates allergic airway disease in human beings. *J Allergy Clin Immunol*, 118:441–446. doi:10.1016/j.jaci.2006.04.047 PMID:16890770
79. Jedrychowski W, Galas A, Pac A *et al.* (2005). Prenatal ambient air exposure to polycyclic aromatic hydrocarbons and the occurrence of respiratory symptoms over the first year of life. *Eur J Epidemiol*, 20:775–782. doi:10.1007/s10654-005-1048-1 PMID:16170661
80. Van Larebeke NA, Birnbaum LS, Boogaerts MA *et al.* (2005). Unrecognized or potential risk factors for childhood cancer. *Int J Occup Environ Health*, 11:199–201. PMID:15875896
81. Perera FP (2000). Molecular epidemiology: on the path to prevention? *J Natl Cancer Inst*, 92:602–612. doi:10.1093/jnci/92.8.602 PMID:10772677
82. Whyatt RM, Jedrychowski W, Hemminki K *et al.* (2001). Biomarkers of polycyclic aromatic hydrocarbon-DNA damage and cigarette smoke exposures in paired maternal and newborn blood samples as a measure of differential susceptibility. *Cancer Epidemiol Biomarkers Prev*, 10:581–588. PMID:11401906
83. Perera FP, Tang D, Tu YH *et al.* (2004). Biomarkers in maternal and newborn blood indicate heightened fetal susceptibility to procarcinogenic DNA damage. *Environ Health Perspect*, 112:1133–1136. doi:10.1289/ehp.6833 PMID:15238289
84. Perera FP, Tang D, Whyatt RM *et al.* (2004). Comparison of PAH-DNA adducts in four populations of mothers and newborns in the US, Poland, and China [Abstract #1975]. *Proc Am Assoc Cancer Res*, 45.
85. Calabrese EJ. Age and susceptibility to toxic substances. New York (NY): John Wiley and Sons; 1986.
86. Laib RJ, Klein KP, Bolt HM (1985). The rat liver foci bioassay: I. Age-dependence of induction by vinyl chloride of ATPase-deficient foci. *Carcinogenesis*, 6:65–68. doi:10.1093/carcin/6.1.65 PMID:3155670
87. Hagmar L, Brøgger A, Hansteen IL *et al.* (1994). Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. *Cancer Res*, 54:2919–2922. PMID:8187078
88. Bonassi S, Hagmar L, Strömberg U *et al.*; European Study Group on Cytogenetic Biomarkers and Health (2000). Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. *Cancer Res*, 60:1619–1625. PMID:10749131
89. Bocskay KA, Tang D, Orjuela MA *et al.* (2005). Chromosomal aberrations in cord blood are associated with prenatal exposure to carcinogenic polycyclic aromatic hydrocarbons. *Cancer Epidemiol Biomarkers Prev*, 14:506–511. doi:10.1158/1055-9965.EPI-04-0566 PMID:15734979
90. Pluth JM, Ramsey MJ, Tucker JD (2000). Role of maternal exposures and newborn genotypes on newborn chromosome aberration frequencies. *Mutat Res*, 465:101–111. PMID:10708975
91. Ross JA (1998). Maternal diet and infant leukemia: a role for DNA topoisomerase II inhibitors? *Int J Cancer Suppl*, 11 S11:26–28. doi:10.1002/(SICI)1097-0215(1998)78:11+<26::AID-IJC8>3.0.CO;2-M PMID:9876473
92. Chen S, Tang D, Xue K *et al.* (2002). DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. *Carcinogenesis*, 23:1321–1325. doi:10.1093/carcin/23.8.1321 PMID:12151350
93. Tang D, Cho S, Rundle A *et al.* (2002). Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. *Breast Cancer Res Treat*, 75:159–166. doi:10.1023/A:1019693504183 PMID:12243508
94. Ford AM, Ridge SA, Cabrera ME *et al.* (1993). In utero rearrangements in the trithorax-related oncogene in infant leukaemias. *Nature*, 363:358–360. doi:10.1038/363358a0 PMID:8497319
95. Gill Super HJ, Rothberg PG, Kobayashi H *et al.* (1994). Clonal, nonconstitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23. *Blood*, 83:641–644. PMID:8298125
96. Ford AM, Pombo-de-Oliveira MS, McCarthy KP *et al.* (1997). Monoclonal origin of concordant T-cell malignancy in identical twins. *Blood*, 89:281–285. PMID:8978302
97. Ford AM, Bennett CA, Price CM *et al.* (1998). Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. *Proc Natl Acad Sci USA*, 95:4584–4588. doi:10.1073/pnas.95.8.4584 PMID:9539781
98. Wiemels JL, Cazzaniga G, Daniotti M *et al.* (1999). Prenatal origin of acute lymphoblastic leukaemia in children. *Lancet*, 354:1499–1503. doi:10.1016/S0140-6736(99)09403-9 PMID:10551495
99. Gale KB, Ford AM, Repp R *et al.* (1997). Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. *Proc Natl Acad Sci USA*, 94:13950–13954. doi:10.1073/pnas.94.25.13950 PMID:9391133
100. Maia AT, Ford AM, Jalali GR *et al.* (2001). Molecular tracking of leukemogenesis in a triplet pregnancy. *Blood*, 98:478–482. doi:10.1182/blood.V98.2.478 PMID:11435320
101. Yagi T, Hibi S, Tabata Y *et al.* (2000). Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia. *Blood*, 96:264–268. PMID:10891460
102. Fasching K, Panzer S, Haas OA *et al.* (2000). Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia. *Blood*, 95:2722–2724. PMID:10753857
103. Wiemels JL, Xiao Z, Buffler PA *et al.* (2002). In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. *Blood*, 99:3801–3805. doi:10.1182/blood.V99.10.3801 PMID:11986239
104. Faustman EM, Silbernagel SM, Fenske RA *et al.* (2000). Mechanisms underlying Children's susceptibility to environmental toxicants. *Environ Health Perspect*, 108 Suppl 1:13–21. doi:10.2307/3454629 PMID:10698720
105. Kreider ML, Aldridge JE, Cousins MM *et al.* (2005). Disruption of rat forebrain development by glucocorticoids: critical perinatal periods for effects on neural cell acquisition and on cell signaling cascades mediating noradrenergic and cholinergic neurotransmitter/neurotrophic responses. *Neuropsychopharmacology*, 30:1841–1855. doi:10.1038/sj.npp.1300743 PMID:15841102
106. Slotkin TA (2004). Guidelines for developmental neurotoxicity and their impact on organophosphate pesticides: a personal view from an academic perspective. *Neurotoxicology*, 25:631–640. doi:10.1016/S0161-813X(03)00050-0 PMID:15183016

107. Slotkin TA, Tate CA, Ryde IT *et al.* (2006). Organophosphate insecticides target the serotonergic system in developing rat brain regions: disparate effects of diazinon and parathion at doses spanning the threshold for cholinesterase inhibition. *Environ Health Perspect*, 114:1542–1546. doi:10.1289/ehp.9337 PMID:17035140
108. Chanda SM, Pope CN (1996). Neurochemical and neurobehavioral effects of repeated gestational exposure to chlorpyrifos in maternal and developing rats. *Pharmacol Biochem Behav*, 53:771–776. doi:10.1016/0091-3057(95)02105-1 PMID:8801577
109. Campbell CG, Seidler FJ, Slotkin TA (1997). Chlorpyrifos interferes with cell development in rat brain regions. *Brain Res Bull*, 43:179–189. doi:10.1016/S0361-9230(96)00436-4 PMID:9222531
110. Baghurst PA, McMichael AJ, Wigg NR *et al.* (1992). Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. *N Engl J Med*, 327:1279–1284. doi:10.1056/NEJM 199210293271805 PMID:1383818
111. Bellinger DC, Stiles KM, Needleman HL (1992). Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. *Pediatrics*, 90:855–861. PMID:1437425
112. Needleman HL, Gatsonis CA (1990). Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. *JAMA*, 263:673–678. doi:10.1001/jama.263.5.673 PMID:2136923
113. Lanphear BP, Dietrich K, Auinger P, Cox C (2000). Cognitive deficits associated with blood lead concentrations <10 microg/dL in US children and adolescents. *Public Health Rep*, 115:521–529. doi:10.1093/phr/115.6.521 PMID:11354334
114. Canfield RL, Henderson CR Jr, Cory-Slechta DA *et al.* (2003). Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. *N Engl J Med*, 348:1517–1526. doi:10.1056/NEJMOa022848 PMID:12700371
115. Grandjean P, Weihe P, Burse VW *et al.* (2001). Neurobehavioral deficits associated with PCB in 7-year-old children prenatally exposed to seafood neurotoxicants. *Neurotoxicol Teratol*, 23:305–317. doi:10.1016/S0892-0362(01)00155-6 PMID:11485834
116. Rauh VA, Garfinkel R, Perera FP *et al.* (2006). Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first three years of life among inner-city children. *Pediatrics*, 118:1845–1859. doi:10.1542/peds.2006-0338.
117. Perera FP, Rauh V, Whyatt RM *et al.* (2005). A summary of recent findings on birth outcomes and developmental effects of prenatal ETS, PAH, and pesticide exposures. *Neurotoxicology*, 26:573–587. doi:10.1016/j.neuro.2004.07.007 PMID:16112323
118. Perera FP, Li Z, Whyatt R *et al.* (2009). Prenatal airborne polycyclic aromatic hydrocarbon exposure and child IQ at age 5 years. *Pediatrics*, 124:e195–e202. doi:10.1542/peds.2008-3506 PMID:19620194
119. Perera FP, Rauh V, Whyatt RM *et al.* (2006). Effect of prenatal exposure to airborne polycyclic aromatic hydrocarbons on neurodevelopment in the first 3 years of life among inner-city children. *Environ Health Perspect*, 114:1287–1292. doi:10.1289/ehp.9084 PMID:16882541
120. Kimmel CA, Collman GW, Fields N, Eskenazi B (2005). Lessons learned for the National Children's Study from the National Institute of Environmental Health Sciences/U.S. Environmental Protection Agency Centers for Children's Environmental Health and Disease Prevention Research. *Environ Health Perspect*, 113:1414–1418. doi:10.1289/ehp.7669 PMID:16203257
121. National Institute of Environmental Health Sciences. Centers for children's environmental health and disease prevention research. 2005. Available from URL: <http://www.niehs.nih.gov/research/supported/centers/prevention/>.
122. Dearth AD, Collman GW, Saint C *et al.* (1999). Building a network of research in children's environmental health. *Environ Health Perspect*, 107 Suppl 3:391–392. doi:10.1289/ehp.99107s3391 PMID:10346987
123. O'Fallon LR, Collman GW, Dearth A (2000). The National Institute of Environmental Health Sciences' research program on children's environmental health. *J Expo Anal Environ Epidemiol*, 10:630–637. doi:10.1038/sj.jea.7500117 PMID:11138655
124. Eskenazi B, Gladstone EA, Berkowitz GS *et al.* (2005). Methodologic and logistic issues in conducting longitudinal birth cohort studies: lessons learned from the Centers for Children's Environmental Health and Disease Prevention Research. *Environ Health Perspect*, 113:1419–1429. doi:10.1289/ehp.7670 PMID:16203258
125. Yiin LM, Rhoads GG, Liroy PJ (2000). Seasonal influences on childhood lead exposure. *Environ Health Perspect*, 108:177–182. doi:10.1289/ehp.00108177 PMID:10656860
126. Thompson B, Coronado GD, Vigoren EM *et al.* (2008). Para niños saludables: a community intervention trial to reduce organophosphate pesticide exposure in children of farmworkers. *Environ Health Perspect*, 116:687–694. doi:10.1289/ehp.10882 PMID:18470300
127. National Children's Study. 2010. Available from URL: <http://www.nationalchildrensstudy.gov/>.
128. Farmer PB, Kaur B, Roach J *et al.* (2005). The use of S-phenylmercapturic acid as a biomarker in molecular epidemiology studies of benzene. *Chem Biol Interact*, 153-154:97–102. doi:10.1016/j.cbi.2005.03.013 PMID:15935804
129. Kotseva K, Popov T (1998). Study of the cardiovascular effects of occupational exposure to organic solvents. *Int Arch Occup Environ Health*, 71 Suppl:S87–S91. PMID:9827890
130. Spanò M, Toft G, Hagmar L *et al.*; INUENDO (2005). Exposure to PCB and p,p'-DDE in European and Inuit populations: impact on human sperm chromatin integrity. *Hum Reprod*, 20:3488–3499. doi:10.1093/humrep/dei297 PMID:16223788
131. Perera FP, Jedrychowski W, Rauh V, Whyatt RM (1999). Molecular epidemiologic research on the effects of environmental pollutants on the fetus. *Environ Health Perspect*, 107 Suppl 3:451–460. doi:10.1289/ehp.99107s3451 PMID:10346993
132. Albertini RJ, Srám RJ, Vacek PM, Lynch J, Nicklas JA, van Sittert NJ, *et al.* Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study. *Res Rep Health Eff Inst* 2003;116:1–141 (discussion 143–162).
133. Ickovics JR, Milan S, Boland R *et al.*; HIV Epidemiology Research Study (HERS) Group (2006). Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities. *AIDS*, 20:1851–1860. doi:10.1097/01.aids.0000244204.95758.15 PMID:16954726
134. Jurewicz A, Matysiak M, Raine CS, Selmaj K (2007). Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. *Neurology*, 68:283–287. doi:10.1212/01.wnl.0000252357.30287.1d PMID:17242333
135. Hernández AF, López O, Rodrigo L *et al.* (2005). Changes in erythrocyte enzymes in humans long-term exposed to pesticides: influence of several markers of individual susceptibility. *Toxicol Lett*, 159: 13–21. doi:10.1016/j.toxlet.2005.04.008 PMID:15922524
136. Perera FP, Weinstein IB (1982). Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. *J Chronic Dis*, 35:581–600. doi:10.1016/0021-9681(82)90078-9 PMID:6282919
137. Perera FP, Santella RM. Carcinogenesis. In: Schulte PA, Perera FP, editors. *Molecular epidemiology: principles and practices*. New York (NY): Academic Press, Inc; 1993. p. 277–300.
138. National Research Council. *Regulating pesticides in food: The Delaney Paradox*. Washington (DC): National Academy of Sciences, National Academy Press; 1987.